Home > Riviste > Minerva Orthopedics > Fascicoli precedenti > Minerva Ortopedica e Traumatologica 2019 June;70(2) > Minerva Ortopedica e Traumatologica 2019 June;70(2):59-64

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE   

Minerva Ortopedica e Traumatologica 2019 June;70(2):59-64

DOI: 10.23736/S0394-3410.19.03927-4

Copyright © 2019 EDIZIONI MINERVA MEDICA

lingua: Inglese

Evaluation of knee periosteal and cartilage morphology in subjects with arthrosis: management with Movardol

Gianni BELCARO 1 , Beatrice FERAGALLI 1, Umberto CORNELLI 1, Roberto COTELLESE 1, Shu HU 1, Mark DUGALL 1, Giancarlo BOLOGNESI 2

1 Irvine3 Labs, Department of Medical, Oral and Biotechnological Sciences, Chieti-Pescara University, Chieti, Italy; 2 Leonardo Medica srl, Vinci, Florence, Italy



BACKGROUND: This open registry study evaluated progress in osteoarthritis- (OA) related symptoms managed with a new pharma-standard supplement (Movardol, Leonardo Medica, Vinci, Italy).
METHODS: A comparable group of subjects using standard management was considered as an evaluation reference. A previous registry had indicated good tolerability of the supplement and a significant efficacy in improving walking and controlling pain. This study was focused on the evaluation of ultrasound parameters relative to the knee joint in 6 months.
RESULTS: The two groups studied with ultrasound were comparable: the supplement group included 22 males (mean age: 52.3±2.2 years) and the control group 23 (53±2.2 years). The Karnofsky Scale in the supplemented subjects improved from 85.5±4% to 96.3±2.2% compared with a lower variation from 85.2±2% to 91±3.2% in the standard management group (P<0.05). Oxidative stress decreased from 388±9 Carr units to 322±24 in the supplement group in comparison with no significant changes (378±12 at inclusion and 385±13 in the control group) (P<0.05). No side effects or tolerability problems due to the supplementation were observed; there were no dropouts. Out of 22 different ultrasound morphological parameters 8 items were changed at 6 months after supplementation. The observation indicated an improvement (increase P<0.05) in periosteal cartilage (PC) thickness. The irregularity of the PC (0-3 on a scale) was improved (decreased P<0.05). The presence of periosteal “steps” was decreased with the supplement (P<0.05). The higher ultrasound range (white) components of the image at the cartilage level were increased to 16.34% in the scanned images (P<0.05). Elastosonography (considering tissue density and its elasticity) were increased in the supplement group [P<0.05]). The visible “channel” space possibly indicating the presence of fluid and swelling was smaller at 6 months with the supplement (P<0.05). The presence of a diffuse vascularization and inflammation (visible as “redness” and measurable by thermography) was significantly decreased with the supplement (P<0.05) considering the maximum temperature of the area and the global average temperature of the skin over the affected knee (P<0.05).
CONCLUSIONS: This registry indicates that remodeling of the knee cartilage in relatively younger subjects using Movardol may occur in months in association to symptoms control.


KEY WORDS: Osteoarthritis; Knee joint; Cartilage; Dietary supplements; Pain; Ultrasonography

inizio pagina